問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2025-03-04

黃立民Huang, Li-Min
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃立民

List

66Cases

2010-06-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-09-20 - 2022-12-31

Phase II

A Phase 2A, 2-Part Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Ceftazidime and Avibactam in Neonates and Infants From Birth to Less Than 3 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment

  • Condition/Disease

    Gram-negative Bacterial Infection

  • Test Drug

    ceftazidime-avibactam

Participate Sites
7Sites

Recruiting7Sites

2019-08-22 - 2021-08-25

Phase I

A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRMED NOSOCOMIAL PNEUMONIA, INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA

  • Condition/Disease

    Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

  • Test Drug

    ceftazidime-avibactam

Participate Sites
7Sites

Recruiting7Sites

2016-05-01 - 2018-12-31

Phase II

A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus (RSV) Infection

  • Test Drug

    AK0529

Participate Sites
4Sites

Terminated4Sites

2013-03-18 - 2016-11-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-09-01 - 2018-09-04

Phase III

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to NonAdjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

  • Condition/Disease

    Vaccines to prevent influenza

  • Test Drug

    aQIV

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB